Corcept Therapeutics (CORT) Capital Expenditures (2012 - 2026)

Corcept Therapeutics has disclosed Capital Expenditures across 15 years of filings, most recently posting $201000.0 for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $201000.0, up 93.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $308000.0 (down 86.47% YoY), and the FY2025 annual result was $211000.0, down 90.29% from the prior year.
• Capital Expenditures came in at $201000.0 for Q1 2026 at Corcept Therapeutics, up from $50000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $1.6 million in Q3 2024 to a low of $12000.0 in Q1 2022.
• The 5-year median for Capital Expenditures is $102000.0 (2023), against an average of $241230.8.
• Across the five-year window, Capital Expenditures plunged 90.48% in 2022 and soared 4318.92% in 2024, its largest moves.
• Corcept Therapeutics' Capital Expenditures stood at $31000.0 in 2022, then gained by 19.35% to $37000.0 in 2023, then surged by 227.03% to $121000.0 in 2024, then sank by 58.68% to $50000.0 in 2025, then jumped by 302.0% to $201000.0 in 2026.
• The last three Capital Expenditures figures came in at $201000.0 (Q1 2026), $50000.0 (Q4 2025), and $57000.0 (Q2 2025), per Business Quant data.